Steven R Laviolette
Overview
Explore the profile of Steven R Laviolette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
2263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
De Felice M, Chen C, Rodriguez-Ruiz M, Szkudlarek H, Lam M, Sert S, et al.
Neuropsychopharmacology
. 2022 Nov;
48(3):540-551.
PMID: 36402837
Chronic exposure to Δ-9-tetrahydrocannabinol (THC) during adolescence is associated with long-lasting cognitive impairments and enhanced susceptibility to anxiety and mood disorders. Previous evidence has revealed functional and anatomical dissociations between...
12.
Scheyer A, Laviolette S, Pelissier A, Manzoni O
Cannabis Cannabinoid Res
. 2022 Oct;
8(1):12-23.
PMID: 36301550
Cannabis consumption during adolescence is an area of particular concern, owing to changes in the social and political perception of the drug, and presents a scientific, medical, and economic challenge....
13.
Maternal Delta-9-Tetrahydrocannabinol Exposure Induces Abnormalities of the Developing Heart in Mice
Robinson G, Ye F, Lu X, Laviolette S, Feng Q
Cannabis Cannabinoid Res
. 2022 Oct;
9(1):121-133.
PMID: 36255470
Cannabis is increasingly being consumed by pregnant women for recreational purposes as well as for its antiemetic and anxiolytic effects despite limited studies on its safety during pregnancy. Importantly, phytocannabinoids...
14.
Sarikahya M, Cousineau S, De Felice M, Lee K, Wong K, DeVuono M, et al.
eNeuro
. 2022 Sep;
9(5).
PMID: 36171057
Despite increased prevalence of maternal cannabis use, little is understood regarding potential long-term effects of prenatal cannabis exposure (PCE) on neurodevelopmental outcomes. While neurodevelopmental cannabis exposure increases the risk of...
15.
16.
Uzuneser T, Szkudlarek H, Jones M, Nashed M, Clement T, Wang H, et al.
Cereb Cortex
. 2022 Jun;
33(6):2470-2484.
PMID: 35650684
The endocannabinoid (eCB) system represents a promising neurobiological target for novel anxiolytic pharmacotherapies. Previous clinical and preclinical evidence has revealed that genetic and/or pharmacological manipulations altering eCB signaling modulate fear...
17.
Hudson R, Norris C, Szkudlarek H, Khan D, Schmid S, Rushlow W, et al.
Psychopharmacology (Berl)
. 2021 Dec;
239(2):509-524.
PMID: 34860284
Rationale: Δ-tetrahydrocannabinol (THC) is the primary psychoactive compound in cannabis and is responsible for cannabis-related neuropsychiatric side effects, including abnormal affective processing, cognitive and sensory filtering deficits and memory impairments....
18.
De Felice M, Laviolette S
Int J Mol Sci
. 2021 Aug;
22(15).
PMID: 34360626
Neurodevelopmental exposure to psychoactive compounds in cannabis, specifically THC, is associated with a variety of long-term psychopathological outcomes. This increased risk includes a higher prevalence of schizophrenia, mood and anxiety...
19.
Oke S, Lee K, Papp R, Laviolette S, Hardy D
Int J Mol Sci
. 2021 Jul;
22(14).
PMID: 34299119
The rates of gestational cannabis use have increased despite limited evidence for its safety in fetal life. Recent animal studies demonstrate that prenatal exposure to Δ9-tetrahydrocannabinol (Δ9-THC, the psychoactive component...
20.
Lee K, Laviolette S, Hardy D
Pediatr Res
. 2021 Apr;
90(3):532-539.
PMID: 33879850
Background: Cannabis use in pregnancy leads to fetal growth restriction (FGR), but the long-term effects on cardiac function in the offspring are unknown, despite the fact that fetal growth deficits...